Enteris And Sanofi Combine To Treat Diabetes
Complete the form below to unlock access to ALL audio articles.
Enteris BioPharma, Inc., has announced the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Sanofi is further validation of the tremendous value our Peptelligence platform program offers in the therapeutic peptide field. We are excited to work with an industry leader like Sanofi.”
This article has been republished from materials provided by Enteris. Note: material may have been edited for length and content. For further information, please contact the cited source.
